AbbVie Inc. (NYSE: ABBV) is rewarding its shareholders once again with a quarterly dividend of $1.64, payable on Friday, Feb.

Johnson & Johnson may outshine AbbVie as a top defensive stock pick. Read how Ben Graham's framework evaluates each ...

The creation of AbbVie In 2011, Abbott announced it was to separate into two leading healthcare companies by the end of 2012. One was to be a diversified medical products company – Abbott ...

AbbVie Inc . (NYSE:ABBV), currently trading at $190.14, has demonstrated resilience and strategic foresight as it navigates the loss of exclusivity for its blockbuster drug Humira. The ...

That's a good analogy for AbbVie, which must continually create new products to replace treatments whose patents expire. The great news is that AbbVie has seemingly done that with its new ...

AbbVie has been named a Top Socially Responsible ... considerations like the environmental impact of the company's products and services, as well as the company's efficiency in terms of its ...

and despite setbacks on its way to market has become one of AbbVie's fastest-growing products with sales expected to reach around $2.2 billion this year, up from just over $1.7 billion in 2021.

AbbVie cautions that these forward-looking statements ... competition from other products, difficulties inherent in the research and development process, adverse litigation or government action ...

AbbVie CEO Robert Michael will soon add the role of board chairman to his résumé. Michael, who became CEO of the North Chicago-based pharmaceutical giant last summer, will assume duties as ...

Danaher, Recursion Pharmaceuticals, Moderna, Thermo Fisher Scientific, AbbVie, Vertex Pharmaceuticals, and Cognizant Technology Solutions are the seven Biotech stocks to watch today, according to ...

Collaboration will combine AbbVie’s oncology expertise and Xilio’s proprietary tumor-activation technology to develop novel immunotherapies, ...